Lung Cancer Clinical Trials

Ongoing Lung Cancer Trials @ NCIS - Patient Recruitment

Protocol Title and Number
A phase II with a lead in phase I study to examine the tolerability, safety profile and efficacy of Hydroxychloroquine and Gefitinib in advanced Non-Small Cell Lung Cancer
INSPIRE – Stimuvax trial In Asian NSCLC Patients: stimulating Immune Response A multi-national, double-blind, placebo-controlled, randomized, phase III clinical trial of the cancer vaccine Stimuvax® (L-BLP25 or BLP25 liposome vaccine) in Asian subjects with stage III, unresectable, non-small cell lung cancer (NSCLC) who have demonstrated either stable disease or objective response following primary chemo-radiotherapy
A Multicenter, Open-Label Phase 2 Study of the Safety and Activity of Lenvatinib (E7080) in Subjects with KIF5B RET Positive Adenocarcinoma of the Lung
A phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy (platinum doublet) and crizotinib
A phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK-rearranged (ALK-positive), stage IIIB or IV, non-squamous non-small cell lung cancer
A Phase Ib/II Multicenter, Randomized, Open Label Trial to Compare MSC2156119J Combined with Gefitinib Versus Chemotherapy as Second-line Treatment in Subjects with MET Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation and Having Acquired Resistance to First-line Gefitinib
A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients with PD L1-POSITIVE Locally Advanced or Metastatic Non-Small Cell Lung Cancer


Contact Information

Are you interested to participate in a clinical trial?

To find out if you are eligible for a particular clinical trial, talk to your doctor at our Cancer Centre today.

For more information please contact:

Ms Vilianty
Clinical Research Administrator
DID : +65 6772 4619


Miss Joan Phee
Research Administrator
DID : +65 6772 2404